SHP2 Inhibition Influences Therapeutic Response to Tepotinib in Tumors with MET Alterations

SHP2 Inhibition Influences Therapeutic Response to Tepotinib in Tumors with MET Alterations

Summary: Tepotinib is an oral MET inhibitor approved for metastatic non-small cell lung cancer (NSCLC) harboring MET exon 14 (METex14) skipping mutations. Examining treatment-naive or tepotinib-resistant cells with MET amplification or METex14 skipping mutations identifies other receptor tyrosine ki...

Full description

Bibliographic Details
Main Authors: Linda Pudelko, Frank Jaehrling, Christof Reusch, Santiago Viteri, Christopher Stroh, Nina Linde, Michael P. Sanderson, Doreen Musch, Catherine Jorand Lebrun, Marina Keil, Christina Esdar, Andree Blaukat, Rafael Rosell, Karl Maria Schumacher, Niki Karachaliou
Format: Article
Language:English
Published: Elsevier 2020-12-01
Series:iScience
Subjects:
Treatment
Cancer
Online Access:http://www.sciencedirect.com/science/article/pii/S2589004220310294

Internet

http://www.sciencedirect.com/science/article/pii/S2589004220310294

Similar Items